Boya Bio receives drug registration in Dominican Republic

Boya Bio-Pharmaceutical Group (SZSE:300294) announced that it has received a "Drug Registration Certificate" from the Dominican Republic's Ministry of Public Health and Social Assistance for its human immunoglobulin (pH4) product. The registration, numbered RM2024-2192, signifies approval for the import and sale of the drug in the Dominican Republic. The product, named IVGLOBE, is a synthetic drug manufactured in China and comes in a 5g/100ml (5% w/v) injectable solution. It should be stored at 2-8°C, protected from light, and has a shelf life of 36 months. The certificate is valid until August 12, 2029. The company noted that actual sales volume and timing in the Dominican Republic market are subject to uncertainties including policy changes, market competition and exchange rate fluctuations.